Literature DB >> 8619596

Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.

G J Yuen1, G L Drusano, C Fletcher, E Capparelli, J D Connor, J P Lalezari, L Drew, S Follansbee, D Busch, M Jacobson.   

Abstract

We examined the pharmacokinetics of ganciclovir in different populations of cytomegalovirus (CMV)-infected patients through the use of nonlinear mixed-effects modelling. As expected, patient weight and estimated creatinine clearance were shown to be important covariates in the serum ganciclovir clearance. Unexpectedly, major differences in ganciclovir clearance between different populations of patients were found. Human immunodeficiency virus (HIV)-infected patients with CMV retinitis cleared ganciclovir 41% faster than HIV-infected patients only shedding CMV into the urine. Solid-organ transplant patients had a serum clearance one-fourth that of HIV-infected patients, even with correction for creatinine clearance. These findings require prospective validation and may have important implications for ganciclovir dosing in different populations of CMV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8619596      PMCID: PMC162943          DOI: 10.1128/AAC.39.10.2350

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

4.  Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.

Authors:  A Erice; M C Jordan; B A Chace; C Fletcher; B J Chinnock; H H Balfour
Journal:  JAMA       Date:  1987-06-12       Impact factor: 56.272

5.  Human pharmacokinetics of the antiviral drug DHPG.

Authors:  C Fletcher; R Sawchuk; B Chinnock; P de Miranda; H H Balfour
Journal:  Clin Pharmacol Ther       Date:  1986-09       Impact factor: 6.875

Review 6.  Concomitant ganciclovir and zidovudine treatment for cytomegalovirus retinitis in patients with HIV infection: an approach to treatment.

Authors:  D Causey
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

7.  Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir.

Authors:  D L Dunn; J L Mayoral; K J Gillingham; C M Loeffler; K L Brayman; M A Kramer; A Erice; H H Balfour; C V Fletcher; R M Bolman
Journal:  Transplantation       Date:  1991-01       Impact factor: 4.939

8.  Diagnosis and treatment of cytomegalovirus disease in transplant patients based on gastrointestinal tract manifestations.

Authors:  J L Mayoral; C M Loeffler; C G Fasola; M A Kramer; W J Orrom; A J Matas; J S Najarian; D L Dunn
Journal:  Arch Surg       Date:  1991-02

9.  Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study.

Authors:  D T Dieterich; D P Kotler; D F Busch; C Crumpacker; C Du Mond; B Dearmand; W Buhles
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

10.  Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy.

Authors:  B D Kuppermann; J I Quiceno; M Flores-Aguilar; J D Connor; E V Capparelli; C H Sherwood; W R Freeman
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

  10 in total
  7 in total

1.  Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group.

Authors:  X J Zhou; W Gruber; G Demmler; R Jacobs; P Reuman; S Adler; M Shelton; R Pass; B Britt; J M Trang; R J Whitley; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.

Authors:  A Caldés; H Colom; Y Armendariz; M J Garrido; I F Troconiz; S Gil-Vernet; N Lloberas; L Pou; C Peraire; J M Grinyó
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

3.  Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome--a population pharmacokinetic study.

Authors:  S Mouly; G Aymard; J P Tillement; C Caulin; J F Bergmann; S Urien
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 4.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

5.  Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.

Authors:  Thomas Tängdén; Pier Giorgio Cojutti; Jason A Roberts; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

Review 6.  Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.

Authors:  Nancy Perrottet; Laurent A Decosterd; Pascal Meylan; Manuel Pascual; Jerome Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients.

Authors:  Thomas Horvatits; Reinhard Kitzberger; Andreas Drolz; Christian Zauner; Walter Jäger; Michaela Böhmdorfer; Stefanie Kraff; Achim Fritsch; Florian Thalhammer; Valentin Fuhrmann; Peter Schenk
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.